News & Updates

Ixekizumab effective for difficult-to-treat psoriatic arthritis
Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021 byAudrey Abella

The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.

Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021